Get Started in Minutes
How Udenyca Copay Assistance Works
1 – Check Your Coverage/Benefits Verification
Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.
2 – Transfer Prescription to AmeriPharma
We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.
3 – Prior Authorization
Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.
4 – Copay Assistance & Financial Aid
We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma Specialty Care has secured $55 million in financial assistance for our patients.
5 – Nursing Care Coordination
AmeriPharma puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.
6 – Delivery Coordination
Medications are always delivered in strict compliance with the specific requirements for immune globulin shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.
What Is Udenyca?
Udenyca is a biosimilar (similar in molecular structure and function) of pegfilgrastim.
Pegfilgrastim is a medication that supports the growing process of stem cells in the bone marrow and aids patients who undergo chemotherapy in replenishing their white blood cell count. Pegfilgrastim contains a PEG (polyethylene glycol) component compared to filgrastim. This allows this medication to stay in the body longer, which leads to less dosing frequency.
Udenyca is a man-made product that mimics a substance in our bodies. It helps stimulate the growth of neutrophils in the human body, which plays a big role in protecting the patient against infections.
What is Udenyca Used For?
Udenyca is a biosimilar injection. Biosimilars are FDA-approved medications that are made to be as safe and effective as the original biologics. There are no clinically meaningful differences between a biosimilar and the original medication.
Udenyca is an FDA-approved medication that is administered after chemotherapy to help reduce the incidence of infections. Patients with non-myeloid malignancies who receive myelosuppressive anti-cancer medications are usually susceptible to an increased risk for febrile (showing fever) neutropenia (lower than normal neutrophil count). This decreases the patient’s ability to fight off infection and puts a patient at greater risk of getting one. Neutrophils are a type of white blood cell that helps in fighting an infection and Udenyca can play a role in repleting one’s neutrophil count.
Copay and Financial Assistance
AmeriPharma Specialty Care alleviates financial burdens for patients and their families
Advanced software locates funding sources to match you with top-dollar foundation programs
One of our copay assistance specialists will assist with the application process
Automatic updates will be sent to you and your physician on the status of the funding
Udenyca Side Effects
Serious side effects include:
- Spleen rupture – enlargement of the spleen may lead to spleen rupture which can cause pain in the left upper stomach area
- Acute respiratory distress syndrome (ARDs) – fluid leakage in the lungs that can lead to serious lung problems such as:
- Shortness of breath with or without fever
- Trouble breathing
- Fast rate of breathing
- Myelodysplastic syndrome and acute myeloid leukemia – Udenyca may increase the risk of blood cancer in patients who have breast or lung cancer
- Leukocytosis (increased white blood cell count)
- Glomerulonephritis (kidney injury)
- Swelling in the face or ankle
- Blood in the urine
- Severe allergic reactions (anaphylaxis) such as:
- Full body rash
- Shortness of breath
- Increased heart rate
- Sickle cell crisis – Using Udenyca in patients with sickle cell anemia may lead to death
Common side effects include:
- Bone pain
- Pain in the legs and arms
Udenyca Administration Information
Udenyca comes in a 6 mg/0.6 ml prefilled syringe. Udenyca is administered subcutaneously, into the fatty layer between the muscle and the skin. It is administered once per chemotherapy cycle after the completion of the chemotherapy regimen. For pediatric patients weighing less than 10 kg, administer 0.1 mg/kg of Udenyca. Administration of less than 0.6 ml is not recommended as it may potentially lead to dosing errors.
Do not administer Udenyca between 14 days before or 24 hours after the administration of cytotoxic chemotherapy.
The carton should be removed from the fridge and left to sit at room temperature for a minimum of 30 minutes prior to injection. Discard any prefilled syringe if left at room temperature for 48 hours or more.
Do not administer Udenyca if there is any discoloration or particulate matter detected in the prefilled syringe.
Avoid use of heat sources (such as tanning beds, heating pads, electric blankets, saunas, and hot tubs). Avoid long, hot baths or sunbathing. Excessive heat may cause your body temperature to rise, potentially causing accelerated metabolism of the drug.
Do not travel, drive, or do other tasks or actions that require alertness during hours 26 through 29 after the injection.